About Index Trending news
Analyze
Top 50 Pricing
Exelixis

Exelixis

Work at Exelixis? Add yourself to this profile

Exelixis

Elsewhere

Alexa global traffic share

Employees

Team size

200+
Locations
The Motley Fool

Exelixis, Inc. Setting New Standard of Care

The Motley Fool

Exelixis, Inc. Gets Some ASCO Love

The Motley Fool

Exelixis, Inc. Rides Cabometyx's Coattails to Big Gains in May

The Motley Fool

These 2 Billionaires Are Dumping Exelixis' Stock. Should You?

Stock markets
The Motley Fool

This New Data Could Push Exelixis' Cabometyx Over $1 Billion in Peak Annual Sales

The Motley Fool

Exelixis, Inc. Prepares for Blastoff

Health Announcements
The Motley Fool

2 Big Reasons Why Shares of Exelixis, Inc. Soared 15% in April

Health Stock markets Earnings
The Motley Fool

Better Buy: Exelixis, Inc. vs. Roche

The Motley Fool

Exelixis, Inc.'s Cabometyx Approved: Let the Kidney Cancer Battle Begin!

The Motley Fool

Exelixis, Inc.'s EKG-Like Stock Chart Hits a Low Spot

Stock markets Health
The Motley Fool

Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb

The Motley Fool

Why Exelixis' Stock Dropped 10% on Tuesday

The Motley Fool

Exelixis, Inc. Partnering Before Approval

The Motley Fool

Exelixis Inc. Stock Was Throttled in February -- Here's Why

Xconomy

On Comeback Trail, Exelixis Reels In $200M Deal For Cancer Drug

Health Earnings
The Motley Fool

Emotional Investing Deflates Exelixis, Inc. in January

The Motley Fool

Why Exelixis, Inc. Rocketed Higher on Friday

Stock markets Health
The Motley Fool

Exelixis, Inc. Nearly Quadrupled in 2015 -- Here's Why --

The Motley Fool

Why Exelixis, Inc. Is Trading Higher Today --

Stock markets Health
The Motley Fool

The FDA Approves Exelixis, Inc's New Cancer Drug --